Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients

Ann Banke*, Morten Schou, Marianne Ewertz, Jordi Dahl, Peter Hartmund Frederiksen, Lars Videbæk, Søren Cold, Jacob E. Møller

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

62 Downloads (Pure)

Abstract

Background: Global longitudinal strain (GLS) is recommended to detect subclinical changes preceding reduced left ventricular ejection fraction (LVEF) in trastuzumab related cardiotoxicity. Since the possibility to detect signs of acute myocardial deterioration at treatment initiation is not clarified, the objective of this study was to assess changes in GLS and biomarkers within the first 2 weeks of trastuzumab treatment. Methods: In a prospective cohort study, 45 patients with non-metastatic breast cancer (age 54, LVEF 62.8%, GLS -19.9%, 40% hypertension) scheduled for trastuzumab treatment were included. Echocardiography and measurement of troponin and NT-proBrain-Natriuretic-Peptide were conducted before initiation of trastuzumab, at days 3, 7, and 14 and after 3, 6, and 9 months. Results: A significant deterioration in LVEF from 62.8% (SD±3.6) to 58.4% (SD±4.1) (p < 0.0001), GLS from -19.9 (SD±2.1) to -18.1 (SD±2.5) (p = 0.004), s’ (p < 0.0001), e’ septal (p = 0.008), and s’ RV (p < 0.0001) occurred at 9 months and was preceded by significant changes in these parameters within the first 14 days. After 14 days, 12 patients (27%) had a ≥10% deterioration in GLS, which was associated with significantly lower LVEF at 55.2% (SD±4.1) at 9 months compared to patients with < 10% early deterioration in GLS (LVEF = 59.5% (SD±3.5) (p = 0.001)). No difference in plasma concentrations of biomarkers was observed between the two groups. Conclusion: In this study deteriorations in key echocardiographic parameters within normal limits were detected during the first 2 weeks of trastuzumab treatment, and an early ≥10% deterioration in GLS was associated with a lower LVEF at 9 months.

Original languageEnglish
JournalEchocardiography
Volume38
Issue number10
Pages (from-to)1702-1710
ISSN1540-8175
DOIs
Publication statusPublished - Oct 2021

Keywords

  • Breast cancer
  • Cardio toxicity
  • Left ventricular function
  • Longitudinal strain
  • Trastuzumab

Fingerprint

Dive into the research topics of 'Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients'. Together they form a unique fingerprint.

Cite this